Medscape2d
SGLT2 Inhibitors Progressing to New Standard After TAVI
In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...
Healthline4d
What Are SGLT2 Inhibitors, and How Do They Work?
SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.
MedPage Today on MSN8d
SGLT2i Improves Outcomes After TAVI
As heart failure patients, the TAVI population studied already is recommended to be treated with an SGLT2 inhibitor, noted ...
Physician's Weekly5d
Optimized Prescribing of SGLT2 Inhibitors and GLP-1 RAs in High-Risk Patients
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Medscape4d
The Role of Kidney in Glucose Homeostasis — SGLT2 Inhibitors, a New Approach in Diabetes Treatment
SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...
Renal & Urology News12d
SGLT2 Inhibitors May Reduce Hospitalization Rates in Myocardial Infarction
SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.
TCTMD6d
Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI
Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...
Healio7d
Oral semaglutide cuts risk for heart events by 14% in high-risk type 2 diabetes
Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...
PharmExec1d
FDA Approves Novartis’ Vanrafia for Primary Immunoglobulin A Nephropathy
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
The American Journal of Managed Care2d
FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
MedPage Today27d
Updated CKD Guidelines Promote Cystatin C, Risk Equations, and SGLT2 Inhibitors
SGLT2 inhibitors are widely recommended for use in most patients. Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's ...